TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23132201

Group type: EXPERIMENTAL
Intervention: Positive physician affect
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Longer visits
Number of subjects: 227
Study: 21262883

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive‐pressure ventilation (NIPPV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 200

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: NIPPV (in infants who received surfactant therapy)
Number of subjects: 200

Group type: COMPARATOR
Intervention: NCPAP (in infants who received surfactant therapy)
Number of subjects: 200
Study: 19333158

Group type: EXPERIMENTAL
Intervention: Capsaicin sensitization
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Menthol sensitization
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (nonsensitized)
Number of subjects: 125
Study: 17107540

Group type: EXPERIMENTAL
Intervention: Bioactive glass S53P4 (BAG)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 23
Study: 15100715

Group type: EXPERIMENTAL
Intervention: High-protein, high-sodium diet (90 g protein/day, 180 mmol sodium/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Moderate-protein, low-sodium diet (70 g protein/day, 65 mmol sodium/day)
Number of subjects: 18
Study: 11059910

Group type: EXPERIMENTAL
Intervention: Lorazepam treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synchronized prime in a flickering 40-Hz display matrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study: 9106934

Group type: EXPERIMENTAL
Intervention: Oral collagen type II (CII) treatment at 10 mg per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral collagen type II (CII) treatment at 1 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8348277

Group type: EXPERIMENTAL
Intervention: 120 mg of i.m. depot methylprednisolone acetate (MPA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 500 mg methylprednisolone (MP) orally
Number of subjects: 41
Study: 2883004

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine JNIH‐6
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (carrier solution of aluminium phosphate)
Number of subjects: 67
Study: 29751193

Group type: EXPERIMENTAL
Intervention: Low added sugar adequate fiber diet (LASAF; 5% total energy from AS and 13.5 g fiber/1000 kcal)
Number of subjects: 32

Group type: COMPARATOR
Intervention: High added sugar low fiber diet (HASLF; 25% total energy from AS and 8.2 g/1000 kcal)
Number of subjects: 32
Study: 26496853

Group type: EXPERIMENTAL
Intervention: BRAF-mutated index TSAs
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: CRCs
Number of subjects: 111
Study: 24992068

Group type: EXPERIMENTAL
Intervention: Short stem prosthesis (Fitmore; Zimmer)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional straight stem prosthesis (CLS; Zimmer)
Number of subjects: 80
Study: 22691145

Group type: EXPERIMENTAL
Intervention: Directed self-regulated learning (DSRL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Instructor-regulated learning (IRL)
Number of subjects: 42
Study: 20417426

Group type: EXPERIMENTAL
Intervention: Minihysteroscopy with saline solution
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Minihysteroscopy with CO(2)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Conventional hysteroscopy with saline solution
Number of subjects: 184

Group type: COMPARATOR
Intervention: Conventional hysteroscopy with CO(2)
Number of subjects: 184
Study: 18538402

Group type: COMPARATOR
Intervention: Monofocal IOL (AR 40)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Multifocal IOLs (Array SA40N, ReZoom, Tecnis ZM900)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Diffractive multifocal IOL (Tecnis ZM900)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Multifocal refractive IOL (Array SA40N)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Multifocal refractive IOL (ReZoom)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Multifocal diffractive IOL (Tecnis ZM900)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Diffractive multifocal IOL
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Refractive multifocal IOLs
Number of subjects: 62

Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 62
Study: 15914535

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 12872556

Group type: EXPERIMENTAL
Intervention: Mupirocin treatment (n = 96)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (n = 95)
Number of subjects: 191
Study: 10572078

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Busulfan
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) within 90 days before BMT
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) discontinued more than 90 days before BMT
Number of subjects: 152
Study: 8537688

Group type: EXPERIMENTAL
Intervention: Pyrimethamine (50 mg) with folinic acid (15 mg) given three times weekly
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study: 1907074

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (200 micrograms intravenous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (400 micrograms intravenous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thyrotropin-releasing hormone
Number of subjects: 0
Study: 7051244

Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) 320 mg plus Sulfamethoxazole (SMZ) 1,600 mg daily for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ampicillin 2 g daily for 14 days
Number of subjects: 20
Study: 31182258

Group type: EXPERIMENTAL
Intervention: Intensive functional rehabilitation (IFR) program
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard care only (Control)
Number of subjects: 104
Study: 30496879

Group type: EXPERIMENTAL
Intervention: Shimming across entire patient volumes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: User-defined region of interest (ROI) shimming strategy
Number of subjects: 21

Group type: COMPARATOR
Intervention: MRI geometric distortions
Number of subjects: 21

Group type: COMPARATOR
Intervention: Dose differences between dCT and CT treatment plans
Number of subjects: 21
Study: 28129130

Group type: EXPERIMENTAL
Intervention: Revusiran (GalNAc-siRNA conjugate) at doses of 2.5-10 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26575246

Group type: EXPERIMENTAL
Intervention: Endoscopic cystectomy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional Sistrunk's surgery
Number of subjects: 32
Study: 23892043

Group type: EXPERIMENTAL
Intervention: PHQ completed before meeting with medical provider (experimental group)
Number of subjects: 101

Group type: COMPARATOR
Intervention: PHQ completed after meeting with medical provider (control group)
Number of subjects: 101
Study: 21417591

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 42

Group type: COMPARATOR
Intervention: Air-abrasive treatment
Number of subjects: 42
Study: 19296243

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 216

Group type: COMPARATOR
Intervention: Spleen-preserving
Number of subjects: 216
Study: 17574448

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 112

Group type: COMPARATOR
Intervention: Carbamazepine/Valproate
Number of subjects: 112
Study: 16027403

Group type: COMPARATOR
Intervention: rosuvastatin 40 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: rosuvastatin 10 mg, increased to 80 mg if INR <3
Number of subjects: 25
Study: 12036422

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 0
Study: 9564459

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Infected symptomatic subjects
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Infected subjects
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham-inoculated subjects
Number of subjects: 74
Study: 7605864

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily and amoxycillin 500 mg three times daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Omeprazole 40 mg once daily and clarithromycin 500 mg three times daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 54
Study: 1965344

Group type: EXPERIMENTAL
Intervention: Nimodipine treatment (0.58 gamma/kg weight/min after a 12.3 gamma/kg weight bolus for 5 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no calcium entry blocker)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nimodipine treatment
Number of subjects: 39
Study: 344835

Group type: EXPERIMENTAL
Intervention: Live attenuated serum inhibitor-resistant influenza B vaccine (R75)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31151100

Group type: EXPERIMENTAL
Intervention: Elective neurosurgery procedures rated by attending neurosurgeons using a need for surgery (NFS) score.
Number of subjects: 9156

Group type: EXPERIMENTAL
Intervention: First-time surgery (craniotomy and spine surgery).
Number of subjects: 9156

Group type: EXPERIMENTAL
Intervention: Spine surgeries with fusion procedures.
Number of subjects: 9156

Group type: EXPERIMENTAL
Intervention: Redo surgery (all types).
Number of subjects: 9156
Study: 28264570

Group type: EXPERIMENTAL
Intervention: Calcination at various temperatures (specific temperatures not provided)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Comparison of sample distributions at each temperature (100, 250, 500, and 750 particles)
Number of subjects: 5
Study: 26341595

Group type: EXPERIMENTAL
Intervention: Fe3O4@PDA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fe3O4@C
Number of subjects: 0
Study: 23237679

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) within 7 days
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) within 7 days
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) between 8 and 14 days
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) between 8 and 14 days
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) after 14 days
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) after 14 days
Number of subjects: 2839
Study: 20605604

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of ropivacaine (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of ropivacaine (group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl use and frequency of pushing a button (FPB) for bolus PCA (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl use and frequency of pushing a button (FPB) for bolus PCA (group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control group C)
Number of subjects: 60
Study: 19959435

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity PA
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Moderate-intensity PA
Number of subjects: 337

Group type: COMPARATOR
Intervention: Vigorous-intensity PA and Moderate-intensity PA
Number of subjects: 337
Study: 17287914

Group type: EXPERIMENTAL
Intervention: Cutting trocars
Number of subjects: 30

Group type: COMPARATOR
Intervention: Blunt trocars
Number of subjects: 30
Study: 14724302

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 2159

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2159
Study: 11578014

Group type: EXPERIMENTAL
Intervention: anti-IFN-gamma
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: anti-TNF-alpha
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 9692113

Group type: EXPERIMENTAL
Intervention: Mini-Wright meter
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Assess meter
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Pulmo-graph meter
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Wright Pocket meter
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Low-range PFMs
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Standard-range PFMs
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: All PFMs
Number of subjects: 309
Study: 7838617

Group type: EXPERIMENTAL
Intervention: Nutritional-Pulmonary Function Score (NPFS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pulmonary Function Score (PFS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Individual PFT parameters
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Percent Ideal Body Weight (%IBW)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Anaerobic Performance (AP)
Number of subjects: 21
Study: 2977392

Group type: EXPERIMENTAL
Intervention: Acitretin administered with food (moderate breakfast)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acitretin administered during a complete fast
Number of subjects: 18
Study: 31987975

Group type: EXPERIMENTAL
Intervention: PENTOCLO (pentoxifylline 800 mg, tocopherol 1000 mg, clodronate 1600 mg 5 days per week)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Triple placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: PENTOCLO
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: PENTOCLO and Triple placebo
Number of subjects: 59
Study: 31530075

Group type: EXPERIMENTAL
Intervention: Novel transosseous device
Number of subjects: 70
Study: 28653319

Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 15 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine
Number of subjects: 270
Study: 26126940

Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 23540442

Group type: EXPERIMENTAL
Intervention: CsA 5 mg/kg continuous infusion over 24 hours
Number of subjects: 37

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 37
Study: 21696957

Group type: EXPERIMENTAL
Intervention: Screen detected invasive cancer with ≥ 30 mm size
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Screen detected invasive cancer with histological grade 3
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Screen detected invasive cancer with heavily node positive (4 or more positive nodes)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Screen detected invasive cancer with vascular invasion positive
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Screen detected invasive cancer displaying mammographic comedo calcification
Number of subjects: 232
Study: 19558398

Group type: EXPERIMENTAL
Intervention: Adding trials to participants' ERP averages (specifically 2 random trials added).
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Internal reliability of the ERN and Pe after adding trials.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Signal-to-noise ratio of the ERN and Pe after adding trials.
Number of subjects: 53
Study: 16401916

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg bid and diclofenac sodium 75 mg for 2-3 weeks (group 1)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and diclofenac in histologically determined cancer cases (group 1)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and diclofenac in BPH and prostatitis cases (group 1)
Number of subjects: 97
Study: 14595084

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate HCL (MPH) at 36 mg or 54 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate HCL (MPH) at 36 mg or lower
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Higher doses of OROS methylphenidate HCL (MPH)
Number of subjects: 47
Study: 10898926

Group type: EXPERIMENTAL
Intervention: Bromperidol at 6 or 12 or 18 mg/day for 3 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nemonapride at 18 mg/day for 3 weeks
Number of subjects: 52
Study: 8967857

Group type: EXPERIMENTAL
Intervention: Metaplasia and dysplasia of epithelial cells
Number of subjects: 0
Study: 1595852

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6611585

Group type: EXPERIMENTAL
Intervention: Urea (1.0 g/kg b.w.)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study: 29136683

Group type: EXPERIMENTAL
Intervention: Meaning-Centered Group Psychotherapy (MCGP)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Supportive group psychotherapy (Control)
Number of subjects: 218
Study: 26362090

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with short-course androgen deprivation therapy (ADT) (4 months of GnRH agonist therapy and antiandrogen)
Number of subjects: 1979

Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: Short-course ADT
Number of subjects: 1979
Study: 25376267

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 200
Study: 22643708

Group type: EXPERIMENTAL
Intervention: Iron-fortified rice (Ultrarice(®)) 50g providing 56.4mg elemental Fe
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard rice (control)
Number of subjects: 216
Study: 20056344

Group type: COMPARATOR
Intervention: Standard thermoplastic masks (SM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Skin‐sparing masks (SSM)
Number of subjects: 20
Study: 18616797

Group type: EXPERIMENTAL
Intervention: Diet and exercise interventions
Number of subjects: 15
Study: 11157353

Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii and Enterococcus faecium SF 68
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S. boulardii
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fermented milks containing Lactobacillus rhamnosus GG
Number of subjects: 0
Study: 9196111

Group type: EXPERIMENTAL
Intervention: Aerosolized gentamicin (GM) 40 mg, twice per day for 3 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.45% saline (saline), twice per day for 3 days
Number of subjects: 28
Study: 8311085

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine (≤5 mg/kg/d)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Second biopsy after further 18 months of therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Long-term cyclosporine therapy
Number of subjects: 14
Study: 3582481

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg o.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg o.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31981567

Group type: EXPERIMENTAL
Intervention: Olfactory Stimulation by L-Menthol (OSM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (Olfactory Stimulation by Strawberry-scented patch)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham condition (breathing through a face mask without OSP)
Number of subjects: 28
Study: 31648099

Group type: EXPERIMENTAL
Intervention: Patritumab + cetuximab + platinum therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo + cetuximab + platinum therapy
Number of subjects: 87
Study: 28950289

Group type: EXPERIMENTAL
Intervention: Glycoengineered imgatuzumab (GA201; 700 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Glycoengineered imgatuzumab (GA201; 1400 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cetuximab (standard dosing)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both antibodies
Number of subjects: 44
Study: 26358336

Group type: EXPERIMENTAL
Intervention: Pollen blocker cream applied three times daily for 30 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo applied three times daily for 30 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pollen blocker cream in adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pollen blocker cream in children
Number of subjects: 0
Study: 22796122

Group type: EXPERIMENTAL
Intervention: Plant sterol/stanol softgel capsules (1.8 g/d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 21185525

Group type: EXPERIMENTAL
Intervention: Breathing awareness meditation (BAM)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Botvin LifeSkills Training (LST)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Health education control (HEC)
Number of subjects: 166
Study: 18164469

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 0
Study: 15935540

Group type: EXPERIMENTAL
Intervention: Direct resin composite restorations
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Indirect resin composite restorations
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ceramic restorations
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (Direct, Indirect, Ceramic)
Number of subjects: 60
Study: 14630439

Group type: EXPERIMENTAL
Intervention: Medium-firm mattress (H(s)=5.6)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Firm mattress (H(s)=2.3)
Number of subjects: 313
Study: 10877012

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rofecoxib 100 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rofecoxib 250 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rofecoxib 375 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32